{"id":"metapramine","rwe":[{"pmid":"34389045","year":"2021","title":"Tricyclic antidepressants versus 'active placebo', placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.","finding":"","journal":"Systematic reviews","studyType":"Clinical Study"},{"pmid":"34034811","year":"2021","title":"Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.","finding":"","journal":"Systematic reviews","studyType":"Clinical Study"},{"pmid":"9076749","year":"1996","title":"The antidepressant metapramine is a low-affinity antagonist at N-methyl-D-aspartic acid receptors.","finding":"","journal":"Neuropharmacology","studyType":"Clinical Study"},{"pmid":"8503619","year":"1993","title":"[Immunoallergic hemolytic anemia caused by metapramine].","finding":"","journal":"Annales de medecine interne","studyType":"Clinical Study"},{"pmid":"1731171","year":"1992","title":"Antinociceptive activity of metapramine in mice. Relationship with its pharmacokinetic properties.","finding":"","journal":"Life sciences","studyType":"Clinical Study"}],"tags":[{"label":"metapramine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antidepressive Agents","category":"pharmacology"},{"label":"Antidepressive Agents, Tricyclic","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"19560 rp","offLabel":[],"synonyms":["metapramine","metapramine fumarate","timaxel","19560-RP","19560 RP"],"timeline":[],"approvals":[],"brandName":"19560 Rp","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"metapramine","explanation":"Imagine your brain is like a computer, and metapramine is a software update that helps fix problems with how the computer is working. It does this by sending signals to the brain's receptors, which are like special buttons that receive and process information. By adjusting the way these receptors work, metapramine can help alleviate symptoms of certain conditions.","oneSentence":"Metapramine is thought to work by interacting with certain receptors in the brain to produce its therapeutic effects.","technicalDetail":"Metapramine is a small molecule that likely acts as a receptor agonist or antagonist, although the specific receptor targets and mechanisms of action are unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1719","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METAPRAMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:36:38.250404","biosimilars":[],"competitors":[],"genericName":"metapramine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"303954M7YF","CHEBI":"CHEBI:134971","INN_ID":"3673","UMLSCUI":"C0066057","ChEMBL_ID":"CHEMBL2106919","PUBCHEM_CID":"65700","SECONDARY_CAS_RN":"93841-84-0","MESH_SUPPLEMENTAL_RECORD_UI":"C012677"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":41,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2021 Aug 13","pmid":"34389045","title":"Tricyclic antidepressants versus 'active placebo', placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.","journal":"Systematic reviews"},{"date":"2021 May 25","pmid":"34034811","title":"Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.","journal":"Systematic reviews"},{"date":"1996","pmid":"9076749","title":"The antidepressant metapramine is a low-affinity antagonist at N-methyl-D-aspartic acid receptors.","journal":"Neuropharmacology"},{"date":"1993","pmid":"8503619","title":"[Immunoallergic hemolytic anemia caused by metapramine].","journal":"Annales de medecine interne"},{"date":"1992","pmid":"1731171","title":"Antinociceptive activity of metapramine in mice. Relationship with its pharmacokinetic properties.","journal":"Life sciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metapramine, a small molecule drug in the metapramine class, is a medication with unknown target and commercial status. Its mechanism of action is not well-documented, and it is not approved by the FDA for any indications. As a result, there is limited information available on its use, efficacy, and safety profile. Further research is needed to fully understand the properties and potential applications of metapramine. Due to the lack of available data, it is not possible to provide a comprehensive summary of this medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}